

AVISIO™



Identifies
BLBC with high
precision and
accuracy.



Tested in over
530
patients in US
clinical trials.



Specificity Sensitivity

90%

75%

PPV

NPV

81%

86%



Designation
2016



Turnaround
time
<24 hours



THREEN DIAGNOSTICS

Personalising cancer diagnostics one gene at a time.



THREEN DIAGNOSTICS

Personalising cancer diagnostics one gene at a time.



Manufactured and Distributed by:

Fortress Diagnostics
Mervyn Russell,
Export Development Manager
mervyn@fortressdiagnostics.com

www.3NDiagnostics.com

3NDX001v2

AVISIO™

FOXC1 IHC Breast Cancer Test
for Basal-Like Breast Cancer




WHO WE ARE

3N Diagnostics is dedicated to making a real difference in personalising cancer diagnostics.

We have developed a new medical diagnostic test, the Avisio™ FOXC1 IHC Breast Cancer Test, that will identify basal-like breast cancer (BLBC), a highly aggressive sub-type of the disease.

With a global breast cancer incidence of 1.7million, the Avisio™ FOXC1 IHC Breast Cancer Test will help patients affected by BLBC through more personalised care plans.



WHAT IS BLBC?

- BLBC is a hormone-independent, aggressive type of breast cancer that is extremely difficult to identify.
- It can currently only be diagnosed two - five years after an initial breast cancer diagnosis.
- By this stage, symptoms are much worse than before and effective therapy may have been compromised.
- BLBC is clinically elusive, often exhibiting a high rate of metastasis to brain and lungs, despite patients being initially lymph node negative.
- BLBC is found across all ethnic groups.
- Women affected by BLBC are usually younger (25 - 45 years of age).
- Incidence of BLBC:



“BLBC often exhibits a high rate of metastasis to brain and lungs.”



WHY USE AVISIO™?

Until now, BLBC lacked specific biomarkers for effective diagnosis.

The FOXC1 protein is a clinically-proven biomarker specific for BLBC.

Avisio™ FOXC1 IHC Breast Cancer Test measures the presence of FOXC1, helping to ensure BLBC is detected with the utmost precision, accuracy, sensitivity and specificity.

There is no way to predict which patients harbour BLBC until symptoms have appeared, meaning **all patients with breast cancer should be tested** with the Avisio™ FOXC1 IHC Breast Cancer Test to assess the presence or absence of BLBC.

